文献速递临床试验与 GCP流行病学与生物统计

评估由教育和反馈组成的多组分干预以减少全科医生开具苯二氮䓬类处方:BENZORED 混合1型整群随机对照试验

Evaluation of a multicomponent intervention consisting of education and feedback to reduce benzodiazepine prescriptions by general practitioners: The BENZORED hybrid type 1 cluster randomized controlled trial.
PubMed 文献 · PLoS Med · 2022-05-06

在西班牙3个卫生区81个初级卫生中心开展整群随机对照试验,全科医生随机分为干预组(41个中心,372名)和对照组(40个中心,377名)。干预包括苯二氮䓬类合理处方工作坊、逐步减量方案、每月处方反馈和支持网页。12个月后干预组苯二氮䓬类处方量较对照组显著下降,长期使用者比例也减少。

要点

  • 干预组12个月苯二氮䓬类处方量较对照组平均减少3.24 DDD/1000人/天(95%CI -4.96至-1.53,p<0.001)。
  • 干预组长期使用者(≥6个月)比例的调整绝对差为-0.36(95%CI -0.55至-0.16,p>0.001)。
  • 干预组65岁以上长期使用者比例的调整绝对差为-0.87(95%CI -1.44至-0.30,p=0.003)。

核心结论

  • 针对全科医生的多组分干预(教育会议、处方反馈和支持网页)使苯二氮䓬类处方量显著减少,长期使用者减少。
  • 尽管效应量小,但普通人群苯二氮䓬类使用率高,大规模实施可能对许多患者健康产生积极影响。

研究设计与样本

  • 多中心两臂整群随机对照试验,在西班牙3个卫生区(巴利阿里群岛、加泰罗尼亚和瓦伦西亚自治区)的初级卫生中心开展,时间为2016年9月至2018年5月。
  • 81个初级卫生中心随机分配至干预组(n=41;372名全科医生)或对照组(n=40;377名全科医生)。
  • 全科医生对分组未设盲,但药剂师、研究人员和试验统计学家对分组设盲。
  • 主要结局基于700名全科医生(对照组351名,干预组349名),比较12个月后每1000居民每日限定日剂量(DDD)的苯二氮䓬类处方变化。
  • 采用意向性治疗(ITT)分析评估所有临床结局;49名全科医生(干预组21名,对照组28名)失访,但所有全科医生均纳入ITT分析。

主要发现

  • 12个月后,干预组总苯二氮䓬类处方较对照组显著下降(平均差:-3.24 DDD/1000人/天,95%CI -4.96至-1.53,p<0.001)。
  • 干预组长期使用者(≥6个月)数量更少,总体调整绝对差为-0.36(95%CI -0.55至-0.16,p>0.001)。
  • 65岁以上长期使用者调整绝对差为-0.87(95%CI -1.44至-0.30,p=0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该整群设计临床试验的关键局限是部分基线特征不平衡。
  • 对照组基线苯二氮䓬类处方率更高,干预组中女性、拥有博士学位和全科住院医师培训师的全科医生更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current benzodiazepine (BZD) prescription guidelines recommend short-term use to minimize the risk of dependence, cognitive impairment, and falls and fractures. However, many clinicians overprescribe BZDs and chronic use by patients is common. There is limited evidence on the effectiveness of interventions delivered by general practitioners (GPs) on reducing prescriptions and long-term use of BZDs. We aimed to evaluate the effectiveness of a multicomponent intervention for GPs that seeks to reduce BZD prescriptions and the prevalence of long-term users. METHODS AND FINDINGS: We conducted a multicenter two-arm, cluster randomized controlled trial in 3 health districts in Spain (primary health centers [PHCs] in Balearic Islands, Catalonia, and Valencian Community) from September 2016 to May 2018. The 81 PHCs were randomly allocated to the intervention group (n = 41; 372 GPs) or the control group (n = 40; 377 GPs). GPs were not blinded to the allocation; however, pharmacists, researchers, and trial statisticians were blinded to the allocation arm. The intervention consisted of a workshop about the appropriate prescribing of BZDs and tapering-off long-term BZD use using a tailored stepped dose reduction with monthly BZD prescription feedback and access to a support web page. The primary outcome, based on 700 GPs (351 in the control group and 349 in the intervention group), compared changes in BZD prescriptions in defined daily doses (DDDs) per 1,000 inhabitants per day after 12 months. The 2 secondary outcomes were the proportion of long-term users (≥6 months) and the proportion of long-term users over age 65 years. Intention-to-treat (ITT) analysis was used to assess all clinical outcomes. Forty-nine GPs (21 intervention group and 28 control group) were lost to follow-up. However, all GPs were included in the ITT analysis. After 12 months, there were a statistically significant decline in total BZD prescription in the intervention group compared to the control group (mean difference: -3.24 DDDs per 1,000 inhabitants per day, 95% confidence interval (CI): -4.96, -1.53, p < 0.001). The intervention group also had a smaller number of long-term users. The adjusted absolute difference overall was -0.36 (95% CI: -0.55, -0.16, p > 0.001), and the adjusted absolute difference in long-term users over age 65 years was -0.87 (95% CI: -1.44, -0.30, p = 0.003). A key limitation of this clustered design clinical trial is the imbalance of some baseline characteristics. The control groups have a higher rate of baseline BZD prescription, and more GPs in the intervention group were women, GPs with a doctorate degree, and trainers of GP residents. CONCLUSIONS: A multicomponent intervention that targeted GPs and included educational meeting, feedback about BZD prescriptions, and a support web page led to a statistically significant reduction of BZD prescriptions and fewer long-term users. Although the effect size was small, the high prevalence of BZD use in the general population suggests that large-scale implementation of this intervention could have positive effects on the health of many patients. TRIAL REGISTRATION: ISRCTN ISRCTN28272199.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Vicens C, Leiva A, Bejarano F, et al. Evaluation of a multicomponent intervention consisting of education and feedback to reduce benzodiazepine prescriptions by general practitioners: The BENZORED hybrid type 1 cluster randomized controlled trial. PLoS Med. 2022. PMID: 35522626. doi:10.1371/journal.pmed.1003983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。